Lexicon Enrolls First Patient in Phase 2b Progress Study of

The PROGRESS study marks initiation of the late-stage development program for AAK1 inhibitor LX9211, with potential to become the first new, non-opioid drug therapy in high-unmet need neuropathic pain in

Related Keywords

Texas , United States , Alina Cocuzza , Craig Granowitz , Lisa Defrancesco , Bristol Myers Squibb , Lexicon Pharmaceuticals Inc , Nasdaq , Exchange Commission , Drug Administration , Lexicon Pharmaceuticals , Fast Track , Multicenter Study , Open Label Extension , Diabetic Peripheral Neuropathic Pain , Average Daily Pain Score , Investor Inquiries , Media Inquiries , Region ,